press releases
DreaMed’s MODI Dose Guidance Solution (DGS) Demonstrates Glycemic Safety and Improved Control in Slovenia Clinical Investigation; Data to Be Presented at ATTD 2026
Single-site study at University Medical Centre Ljubljana met its primary safety endpoint with low time <54 mg/dL, no device-related serious adverse events, and consistent findings across MDI and basal-only cohorts TEL AVIV, Israel & LJUBLJANA, Slovenia — March 11, 2026 DreaMed Diabetes today announced topline results from a prospective clinical investigation of its MODI Dose […]
DreaMed receives FDA clearance for MODI, bringing automated insulin dose recommendations to people with type 2 diabetes using injections
MODI is the first FDA-cleared solution to use glucose-monitoring data to automatically optimize insulin dosing for people with type 2 diabetes across both basal-only and multiple daily injection regimens. PETAH TIKVA, Israel — September 28, 2026 — DreaMed Diabetes Ltd., A global leader in personalized diabetes treatment optimization, announces that the U.S. Food and Drug […]